[ad_1]
Novo Nordisk, the corporate behind Ozempic and Wegovy, revealed a brand new evaluation of the longest study it has performed to date via the lens of long-term weight reduction.
The 17,604-person examine, published in Nature Drugs and presented on the European Congress on Weight problems in Venice, Italy on Tuesday, confirmed for the primary time that weight problems sufferers with out diabetes maintained a ten% common weight reduction over 4 years after taking Wegovy.
“We see that after nearly all of the burden loss is accrued, you do not return and begin to enhance in weight in case you keep on the drug,” Martin Holst Lange, Novo’s growth head, instructed Reuters in an interview.
The findings present that Wegovy is efficient in the long run, over a number of years, offered sufferers keep on it.
Associated: Novo Nordisk Is Worth More Than Denmark’s GDP Thanks to America’s Ozempic and Wegovy Craze
A further evaluation launched Tuesday primarily based on the identical information confirmed that Wegovy had advantages for the guts, no matter how a lot weight examine contributors misplaced whereas taking it.
Wegovy lowered the danger of stroke by 20% in chubby or overweight folks with a historical past of coronary heart illness.
Researchers do not exactly understand how Wegovy’s energetic ingredient, semaglutide, protects the guts, and are conducting research to grasp it.
“We now additionally perceive that whereas we all know that physique weight reduction is necessary, it is not the one factor driving the cardiovascular advantage of semaglutide remedy,” Lange instructed Reuters on Tuesday.
Associated: These U.S. Health Insurers Will Now Cover Wegovy, the Wildly Popular $1,349 Weight-Loss Drug
The information might add to Novo’s case to have its weight reduction medicine be extra broadly coated by insurance coverage firms in nations just like the U.S. and the U.Ok.
Nonetheless, there have been downsides to taking Wegovy recorded within the report — about 17% of those that took the drug left the examine early due to stomach-related points like nausea.
Novo has made Wegovy accessible in 10 nations to date, together with the U.S., Norway, Japan, and Spain, since releasing the drug in 2021. Costs begin at $200 and might attain virtually $2,000 monthly, depending on the country.
Within the U.S., Ozempic goes for about $936 a month out of pocket whereas Wegovy sells for about $1,350 a month.
Costco created a program in April that provides members direct entry to Ozempic and Wegovy when applicable, although the medicine value falls straight on prospects or medical health insurance.
Associated: Costco Announces Ozempic, Wegovy Prescriptions and New Weight Loss Program
Novo stated earlier this month that at the least 25,000 folks within the U.S. begin Wegovy per week.
[ad_2]
Source link
